top of page
    • 3 days ago

Disc Medicine's CEO reviews recent EHA data, including learnings about clinical endpoints from the company's lead GlyT1 program

John Quisel describes how bitopertin aims to reduce PPIX, a photosensitiser that makes it painful for patients when exposed to light. Plus, learnings about clinical endpoints from the company's P2 experience, and highlights on two hepcidin programs.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

@BiotechTVHQ

BiotechTV

BiotechTVHQ

@BiotechTV

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Theragent_Logo-Landscape_red-small.png

Theragent is an advanced therapeutics Contract Development Manufacturing Organization in Arcadia, CA, focused on novel cell and gene therapies for the treatment of cancer and rare diseases. The company’s innovative cGMP facility offers comprehensive end-to-end manufacturing and in-house testing capabilities for clinical and commercial purposes. 

Visit Theragent

bottom of page